MyFinsight
Home
Blog
About
Proceeds from the
issuance of common stock...
$227,413K
Proceeds received
related to employee...
$3,665K
(548.67%↑ Y/Y)
Maturities and sales of
short-term investments
$448,795K
(197.59%↑ Y/Y)
Net cash provided by
financing activities
$231,078K
(10299.55%↑ Y/Y)
Net cash provided by
investing activities
$222,896K
(47.80%↑ Y/Y)
Effect of exchange rate
changes on cash
$1K
(-98.36%↓ Y/Y)
Canceled cashflow
$225,899K
Increase in cash, cash
equivalents and restricted...
$312,851K
(262.32%↑ Y/Y)
Canceled cashflow
$141,124K
Purchase of short-term
investments
$224,990K
Purchases of property and
equipment
$909K
Stock-based compensation
$68,706K
(-85.65%↓ Y/Y)
Accrued liabilities
$20,737K
(328.36%↑ Y/Y)
Accrued compensation
$2,370K
(8.67%↑ Y/Y)
Other current
liabilities
$1,474K
(109.38%↑ Y/Y)
Operating lease
right-of-use assets and lease...
$335K
(452.63%↑ Y/Y)
Depreciation
$46K
(24.32%↑ Y/Y)
Unrealized foreign
exchange loss (gain)
-$30K
(-112.55%↓ Y/Y)
Other non-current
liabilities
$3K
(-88.89%↓ Y/Y)
Net cash used in
operating activities
-$141,124K
(-111.44%↓ Y/Y)
Canceled cashflow
$93,701K
Net loss
-$215,700K
(61.87%↑ Y/Y)
Prepaid expenses and
other current assets
$12,032K
(523.10%↑ Y/Y)
Accounts payable
-$3,907K
(-121.79%↓ Y/Y)
Amortization of discount on
short-term investments
$2,969K
(190.22%↑ Y/Y)
Other assets
$217K
(-90.37%↓ Y/Y)
Back
Back
Cash Flow
summitplc-logo_05fd32df-svg
Summit Therapeutics Inc. (SMMT)
summitplc-logo_05fd32df-svg
Summit Therapeutics Inc. (SMMT)
source: myfinsight.com